Navigation Links
Cardiogenesis Reports Fourth Quarter and Full Year 2010 Results
Date:3/9/2011

IRVINE, Calif., March 9, 2011 /PRNewswire/ -- Cardiogenesis Corporation (OTCQB: CGCP), a leading developer of surgical products used in the treatment of diffuse coronary artery disease, today reported financial results for its fourth quarter and full year ended December 31, 2010.

Revenue for the fourth quarter of 2010 was $2,864,000, a 9% decrease from prior year fourth quarter revenue of $3,132,000.  For full year 2010, revenue was $11,290,000, an increase of 9% over revenue of $10,354,000 in 2009.  The company reported a net loss of $558,000, or $0.01 per basic and diluted share, in the fourth quarter of 2010 as compared with net income of $409,000, or $0.01 per basic and diluted share, in the prior year fourth quarter.

"The company posted a solid performance for both the fourth quarter and full year as our sales organization made the case for TMR and increased product utilization.  Fourth quarter revenues were negatively impacted by lower capital equipment sales as compared to 2009.  In addition the fourth quarter of 2009 included $218,000 of handpiece revenue previously deferred under accounting rules.  Excluding the impact of that non-recurring, deferred revenue, handpiece revenue increased 13% in fourth quarter 2010 over the prior period," said Cardiogenesis Executive Chairman Paul McCormick.  "Continued revenue growth of our commercial products has allowed us to finance significant progress on our clinical and regulatory initiatives.  We enrolled two additional patients in our PHOENIX™ Combination Delivery System clinical feasibility trial, and our team will be in Europe in the upcoming weeks to perform additional procedures.  Moreover we are in the final phase of our animal safety study at the Texas Heart Institute (THI).  This is important because the THI report is a gating item for our submission to the FDA to obtain regulatory clearance to begin a human trial for the PHOENIX System in the
'/>"/>

SOURCE Cardiogenesis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
2. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
3. Cardiogenesis Reports Third Quarter 2009 Results
4. Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010
5. Cardiogenesis (CGCP) Listing Upgraded to New OTCQB(TM) Market for All U.S. Registered and Reporting OTC Securities
6. Cardiogenesis Corporation to Report 2010 Second Quarter Results on August 4th
7. Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
8. Cardiogenesis Enrolls First Two Patients in Its Feasibility Study of the PHOENIX® Combination Delivery System
9. Cardiogenesis Corporation to Report 2010 Third Quarter Results on November 3rd
10. Cardiogenesis Receives Research Award From Federal Government
11. Cardiogenesis Reports Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... SAN FRANCISCO , May 5, 2015 ... a Small Business Innovation Research (SBIR) grant from the ... Creek is a San Francisco ... therapeutics to selectively repair tissues damaged by disease. This ... therapeutics engineered to repair heart tissue following a heart ...
(Date:5/5/2015)... YORK , May 5, 2015  IBM Watson ... is collaborating with more than a dozen leading cancer ... and personalize treatment options for their patients. The institutes ... capabilities to reduce from weeks to minutes the ability ... and gather relevant information from medical literature to personalize ...
(Date:5/5/2015)... , May 5, 2015  The preclinical contract research ... pharmacokinetic testing of drugs and safety testing of medical ... Director of Preclinical Studies, presented at this week,s annual ... Ophthalmology (ARVO) in Denver, CO. ... Assessment of a Novel, Cross-Linked, Bio-Absorbable Carboxymethyl Hyaluronic Acid ...
Breaking Medicine Technology:Silver Creek Pharmaceuticals Awarded NIH SBIR Grant for Smart Growth Factor Technology 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 3Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 4Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 5Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 6Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3
... Yesterday, T he Lancet published online the ... Victoza® (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia®.  The 26-week ... plasma glucose (FPG), and body weight than Januvia®, with similar or ... , , ...
... April 23 Results of a ... g/d significantly improved lipid and glycemic measures in ... fasting glucose and/or impaired glucose tolerance).  The randomized, ... American Association of Clinical Endocrinologists (AACE) 19th Annual ...
Cached Medicine Technology:The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 2The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 3The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 4The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 5The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 6New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 2New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 3New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 4New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 5New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 6New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 7New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 8New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 9New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 10
(Date:5/5/2015)... 2015 ProTexting, LLC – a ... deploy Mobile Engagement Campaigns and other Mobile solutions, introduces ... can now leverage the power of Mobile Marketing to ... subscribers’ e-mail addresses into the Constant Contact Platform. , ... the growing trend of multi-channel marketing would become more ...
(Date:5/5/2015)... DC (PRWEB) May 05, 2015 ... Hope Initiative, a new study aimed at determining how ... patients. RG is an international non-profit providing rare disease ... sequencing technology, connections to scientists and researchers, and help ... crowdfunding. , “I am excited to see how crowdfunding ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 On April ... Los Angeles, CA, Choices Recovery sponsored Durkin Entertainment’s “RockNRolla” ... LA’s leading producer of sustainable product placement in TV ... the world’s top providers of ecologically sound and socially ... premier red carpet event that makes appearances at various ...
(Date:5/5/2015)... Brookfield, Wis. (PRWEB) May 05, 2015 ... security solutions created the Sensatec® ST750 Fall Management Solution ... recording advising the monitored patient or resident to wait ... up. Caregivers also have the choice of 16 different ... into a nurse call system such as Code Alert®. ...
(Date:5/5/2015)... In the upbeat Moms Helping Moms video, real ... support each other. Parenting is a tough job, but ... so much easier. Mothers talk about how relating and ... and help them realize there’s no perfect parent; everyone is ... clearly dear friends share that it's just that, the friendship ...
Breaking Medicine News(10 mins):Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3Health News:Rare Genomics Institute to Study Impact of Crowdfunding on Rare Diseases 2Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 3Health News:Just In Time For Mother’s Day, Healthy Birth Day Releases Video Titled “Moms Helping Moms” Encouraging Mothers To Band Together 2
... ... within football’s international arena, it is with great pleasure that international direct selling identity, ... of Asian football. , ... (PRWEB) February 19, 2010 -- As the Official Direct Selling Supporter of the ...
... magnetic resonance imaging (MRI) may help physicians differentiate between ... wrist enabling more targeted therapies unique to each condition, ... the American Journal of Roentgenology . Contrast-enhanced MRI ... bodily structures. Rheumatoid arthritis ...
... ... ... ... ...
... ... , ... , , , , ... ...
... ... ... ... ...
... Francisco has signed a partnership agreement with Genentech, Inc., ... discover and develop drug candidates for neurodegenerative diseases. ... research acumen in neuroscience and will collaborate with UCSF ... work of several researchers at the UCSF Small Molecule ...
Cached Medicine News:Health News:QuestNet and AFC: Raising the Bar of Asian Football 2Health News:QuestNet and AFC: Raising the Bar of Asian Football 3Health News:Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis 2Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 2Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 3Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 4Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 5Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 6Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 7Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 8Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 9Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 10Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 11Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 12Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 13Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 14Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 15Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 16Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 17Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 18Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 19Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 20Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 21Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 22Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 23Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 24Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 25Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 26Health News:Biotel Announces Results for Second Quarter ended December 31, 2009 2Health News:Biotel Announces Results for Second Quarter ended December 31, 2009 3Health News:Centene Corporation to Webcast Medical Management Systems Update 2Health News:Centene Corporation to Webcast Medical Management Systems Update 3Health News:Centene Corporation to Webcast Medical Management Systems Update 4Health News:UCSF enters drug discovery agreement with Genentech 2Health News:UCSF enters drug discovery agreement with Genentech 3
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
... system uses prolene as thread-guide reducing time and ... Probe is inserted into the nasolacrimal duct and ... The probe is then withdrawn leaving the polypropylene ... diam silicone tubing into place. Newly coated with ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... conforms to natural anatomy of the ... on disposable inserter/dilator instrument for ease ... The Micro-Large plugs feature the unique ... shape of the eyelid. The slightly ...
Medicine Products: